Dr. Alice Huxley of Speedel speaks about the need for commitment to research and innovation.
Dr. Alice Huxley, CEO of Speedel discusses what it takes to launch a successful company. Some companies launch in a garage, while others are launched in an attic. And that was just the beginning! Today Speedel is a Swiss biopharmaceutical company that recently received the Wall Street Journal's Gold Award for Technology Innovation for their work on Aliskiren, the first renin inhibitor for treating hypertension. Dr. Huxley, who will also be presenting at the J.P. Morgan Healthcare Conference during her visit to the Bay Area, will speak about the need for commitment to research and innovation and the importance of developing new drugs rather than "me-too" products- swissnex
Dr. Alice Huxley
Dr. Alice Huxley , CEO and President, previously Global Project Manager at Novartis Pharma AG, has extensive experience in research and drug development process in a matrix type pharmaceutical R&D organization. She led several global multidisciplinary teams that successfully brought innovative drugs to the market.